Researchers have used artificial intelligence techniques to massively accelerate the search for Parkinson's disease treatments. The researchers designed and used an AI-based strategy to identify compounds that block the clumping, or aggregation, of alpha-synuclein, the protein that characterises Parkinson's.
A new study offers a first look into the complex molecular changes that occur in brain cells with Lewy bodies, which are key pathological hallmarks of Parkinson's disease and some dementias. The findings reveal that brain cells with Lewy bodies exhibit a specific gene expression pattern akin to a disease-related fingerprint.
New hypothesis paper builds on a growing scientific consensus that Parkinson's disease route to the brain starts in either the nose or the gut and proposes that environmental toxicants are the likely source.
Lewy body disease may be more common in middle-aged people than previously thought, according to a recent study. In the study, almost one in ten of over 50-year-olds were found to have tissue markers of Lewy body disease in the brain.
Researchers uncovered the mechanistic details behind how several proteins interact to help cells recognize and remove damaged mitochondria. Optineurin (OPTN) and its interactions are needed to provide a contact site for another protein, Tank-binding kinase 1 (TBK1), during this process. The OPTN-TBK1 relationship is necessary for these mitochondria to be recognized and eliminated from the cell. This mechanism may have relevance for developing drugs to treat Parkinson's disease.
